logo
The Taste by Vir Sanghvi: As Ozempic arrives in India, eating habits will change, which is bad news for restaurants

The Taste by Vir Sanghvi: As Ozempic arrives in India, eating habits will change, which is bad news for restaurants

Hindustan Times20-05-2025

Could the nature of the restaurant business be changing? If the experience of the West is anything to go by then: Yes, certainly. And the changes are going to gain momentum.
Dr Ambrish Mithal, India's leading endocrinologist was one of the first doctors in Delhi (perhaps all of India) to recognise how much the new drugs that were coming on the market would change our lifestyles. When most doctors were still reading about Ozempic he was already on to the next generation drug: Mounjaro.
Dr Mithal has an interesting new book coming out about how these drugs will affect our behaviour. Till recently you could only buy them abroad but they are now going to be distributed in India and newer, even more efficient drugs should hit our market next year. Dr Mithal believes that this will make a significant difference to the lifestyles of many of us.
As you probably already know, the technical names of the existing drugs are Semaglutide and Tirzepatide. Both work in the same sort of way. They affect our pleasure centres so that we are satisfied much earlier than normal. This means that we eat less because we feel fuller sooner.
The drugs were invented to fight diabetes which they do extremely well. But they have other effects. If you eat less, which these drugs make you do, then you lose weight. If you lose weight then that affects all the other conditions that excess weight leads to: Heart disease, hypertension etc. There is also new research that suggests that the drugs can have positive effects on your health that are not weight-related.
Once the drugs become easily available in India (by next month, I reckon) doctors will start prescribing them for weight loss. And given how overweight much of our upper middle class is, they will find many takers.
I am sure that this will have huge and beneficial consequences for public health but my concern today is more limited: What will Ozempic and Mounjaro do to the restaurant and food delivery businesses?
Almost all the evidence from America where the drugs have been available for a while is still largely anecdotal. I have not seen any research that provides convincing figures. But the anecdotal evidence points directly to only one set of conclusions: People are now eating less at restaurants and wasting more food than they used to.
The new drugs don't necessarily stop you from being hungry so people go to restaurants anyway. But once they start eating they feel full so quickly — because the drugs affect satiety — that they find it difficult to finish what is on their plates.
So far, restaurants have not had to work out how to cope with this trend. The drugs are expensive and so their use is not widespread enough to justify a change in the entire restaurant industry's approach to dining. But restaurateurs know that as newer weight loss drugs are introduced and patents for the existing drugs run out, prices will drop dramatically. And more and more people will start taking them.
Well, some restaurants are already reducing portion sizes. I expect this trend will gather steam in the months ahead. But fine dining restaurants face a very specific problem. Many of them only serve so-called tasting menus which can be upwards of 10 courses. (At Copenhagen's Alchemist the menu has 70 courses.)
They are now discovering that guests are ready to give up after two or three courses because they are already too full. Also, because it takes a little time for people to realise how full they are, restaurants that speed up the service have more luck. Those that take lengthy pauses between courses discover that by the time they are ready to serve the second course, guests are already complaining that they are too full.
Frankly: Yes. The people who go to fine dining restaurants are, by definition, rich. They can all afford Mounjaro and Ozempic. And most are a little concerned about their weight. They have already started avoiding multi-course tasting menus in the US and Europe and the trend will spread globally.
The only way restaurants will be able to cope is by either going a la carte or by offering smaller set menus. Personally, I don't think that this is such a bad thing. I am fed up of long tasting menus devised by chefs whose confidence is much greater than their skills.
The other effect of the move away from tasting menus will be a shift in power away from the chef. At present at top restaurants the chef acts like he is doing you a favour and expects you to eat whatever he chooses. If we do go back to a la carte system then chefs will have to cook whatever customers select from the menu. And I think that's a good thing.
But it isn't just the fancy places that will be affected. At Indian and Indian-Chinese restaurants most of us order too much. Just the carbs alone are breathtaking: Roti-naan basket, steamed rice plus pulao or biryani. At Chinese restaurants it can be noodles, plain rice and fried rice
Even though the order is too large, we feel obliged to finish it because we have spent good money on the food.
But what happens when we can't finish it because our bodies won't let us? When we start feeling like throwing up after too much matar paneer or chicken manchurian?
After the first couple of times when we have to waste the food we will start ordering less.
Once that happens the size of the average check at restaurants will go down and most restaurants will have to rework their economics.
It will affect delivery too. In America delivery meals are a fact of life: People who don't have the time to cook are forced to order them.
In India, on the other hand, we still regard them as treats; as opportunities to order delicious food we could never make at home. We usually order large meals and eat much more than we would have if we had just eaten home-cooked food.
So, what happens when we find we can no longer eat so much? We will order less. And the delivery boom could be affected.
There is another effect of these drugs that is still being studied: People who take them seem to want to drink less alcohol. Tables that would order two bottles of wine in a restaurant now have difficulty finishing one. In most of the world, wine sales are down. And spirits seem to be losing some of their popularity too. Some of the world's great liquor companies are in crisis because they can't shift their inventories. Not all of this is because of weight loss drugs. But once these drugs become cheaper and widely available, liquor consumption is unlikely to go up.
Will we all be thinner when all this finally happens? Yes, for sure. And healthier too.
And will the restaurant industry be in trouble? Well, not if it finds ways to cope with the drop in appetite. But yes, it will have to rethink its business models.
A change is coming.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

40 women using weight-loss drugs see unexpected pregnancies; prompt UK's warning over contraceptives
40 women using weight-loss drugs see unexpected pregnancies; prompt UK's warning over contraceptives

First Post

time3 hours ago

  • First Post

40 women using weight-loss drugs see unexpected pregnancies; prompt UK's warning over contraceptives

The weight loss drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity read more There have been at least 40 cases of unexpected pregnancies associated with weight loss drugs. Pixabay British health authorities have issued a warning to women using weight-loss medications such as Ozempic, Wegovy and Mounjaro, urging them to use effective contraception after dozens of pregnancy reports linked to the drugs. The Medicines and Healthcare products Regulatory Agency (MHRA) on Friday (May 6) released its first public safety alert addressing the use of weight-loss drugs and contraception. The agency said it had received 40 reports of pregnancies involving users of medications that include the active ingredients semaglutide or tirzepatide, The Guardian reported. STORY CONTINUES BELOW THIS AD Ozempic and Wegovy, which both contain semaglutide, mimic a gut hormone called GLP-1 that helps reduce appetite by slowing digestion and increasing insulin production. Mounjaro, which contains tirzepatide, also targets a second hormone involved in blood sugar and appetite control. Though often referred to as 'weight-loss injections,' not all of the drugs are formally authorised for weight loss. Drugs not advised during pregnancy or attempts to conceive The MHRA said the drugs should not be taken during pregnancy, while trying to conceive, or while breastfeeding due to a lack of safety data. In some cases, the agency recommends that women continue contraception for up to two months after stopping the medication before attempting pregnancy. Among the 40 reports, eight were associated with semaglutide and nine with liraglutide, which is found in the weight-loss drug Saxenda. Two cases were explicitly reported as unintended pregnancies. Dr. Channa Jayasena, a reproductive endocrinologist at Imperial College Healthcare NHS Trust, said the drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity. 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' he said. He also noted that the medications may interfere with the absorption of oral contraceptives due to delayed stomach emptying, although further research is needed. Officials stress responsible use Dr. Alison Cave, the MHRA's chief safety officer, warned that the medications should not be used as quick fixes for weight loss or for cosmetic purposes. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Cave said. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way.' The MHRA said it has published updated guidance to help patients use the medications safely but emphasized that the advice should not replace consultation with a healthcare provider. STORY CONTINUES BELOW THIS AD Dr. Jayasena added that while the risks of GLP-1 drugs in pregnancy are not fully known, similar weight-loss interventions like surgery have been associated with higher miscarriage rates. 'So women are advised to do all they can to prevent pregnancy while taking GLP-1 drugs,' he said.

Diabetes and obesity management drug Mounjaro sees sales rise in India
Diabetes and obesity management drug Mounjaro sees sales rise in India

Business Standard

time8 hours ago

  • Business Standard

Diabetes and obesity management drug Mounjaro sees sales rise in India

Eli Lilly's diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven by increasing demand and a growing number of patients shifting to higher dosages, according to market research firm Pharmarack. In May, volume sales of the 5 mg dose grew by 2.5 times. The drug, launched in India on 20 March this year, is currently available in two injectable dosage forms — 2.5 and 5 milligrams (mg). It is prescribed primarily for patients who meet certain clinical criteria related to obesity and diabetes. Data suggests that both value and quantity sales of the 5 mg form more than doubled from April to May, outperforming the 2.5 mg dosage. Mounjaro 5 mg sales rose from 9,380 units in April (valued at ₹3.08 crore) to 22,940 units in May, valued at ₹7.53 crore. For the 2.5 mg form, demand growth was relatively muted — 19,350 units in May, up from 18,270 units in April. The sales value for May stood at ₹5.08 crore, up marginally from ₹4.8 crore the previous month. However, the steady growth in the 2.5 mg dosage indicates a consistent rise in new patients starting the drug. Patients typically begin treatment with the 2.5 mg dose, which is gradually escalated. 'The almost doubling of sales for the 5 mg form is because existing patients are upgrading to higher doses after four weeks, while new patients are also onboarding Mounjaro in good numbers,' said Sheetal Sapale, vice-president (commercial) at Pharmarack. Treatment with Mounjaro is typically initiated with the lowest available dosage (2.5 mg), administered subcutaneously once a week. 'This starting dose is usually maintained for the first four weeks to help the patient adjust and minimise potential side effects,' said Dr Sukhvinder Singh Saggu, director for minimal access, GI and bariatric surgery at CK Birla Hospital, Delhi. After this initial phase, the dose is commonly increased to 5 mg weekly, as weight-loss outcomes tend to be more pronounced at this level. Experts add that while the 2.5 mg dose helps initiate the process, many patients experience a plateau at that dosage, and shifting to 5 mg allows for more consistent and promising results. Doctors say inquiries for the drug have risen steadily, with Mounjaro now also being prescribed in select cases prior to bariatric surgery. Saggu said many new patients are actively inquiring about the drug, either as a new treatment option or as part of their ongoing weight management plans. 'Some of our existing patients, who were previously prescribed medications like Fenoglide, are now also being considered for Mounjaro as an alternative or add-on therapy,' he added. According to standard guidelines for obesity management medications (OMMs), a patient must have a Body Mass Index (BMI) over 27 with at least one obesity-related comorbidity, such as Type 2 diabetes, hypertension, or high cholesterol. However, doctors are also receiving inquiries from individuals who do not meet the medical criteria. 'We are strictly discouraging its use for cosmetic purposes or in patients who do not meet the clinical threshold,' Saggu said.

Ozempic Side-Effect: Male Users Claim Shocking Change After Taking Weight Loss Drug
Ozempic Side-Effect: Male Users Claim Shocking Change After Taking Weight Loss Drug

NDTV

time8 hours ago

  • NDTV

Ozempic Side-Effect: Male Users Claim Shocking Change After Taking Weight Loss Drug

Men using Ozempic, a popular weight-loss injection, have reported an unexpected side effect - an increase in perceived penis size. Numerous users have taken to online forums and social media platforms to share their experiences, claiming that their private parts appear larger since starting the medication. While anecdotal, these claims have sparked lively conversations, with dozens of men attributing their enhanced confidence and physical changes to the drug. The phenomenon has yet to be formally studied, but it's generating buzz as a surprising potential perk of the weight-loss treatment. One person wrote on Reddit, "I recently measured myself down there and noticed I gained about one inch. Now I think people will say it was because of the fat loss. However, at the time I measured myself before (4 years ago), I was thinner. I also pressed during measurement before, and also this time. Has anyone else noticed this change in themselves?" Another Reddit user shared, "Yes. I gained 1.5 inches in length. No joke. Like you I obviously know how long I was before I got very fat. Then after about seven months on Tirzepatide in my case I gained 1.5 inches in length. Definitely not all from weight loss." Some men attributed it to improved blood flow and reduced pubic fat due to weight loss. However, a Redditor suggested that the apparent size difference might result from varying external conditions, such as temperature or arousal levels, during before-and-after measurements rather than the drug itself. "I feel like nobody is really reading what you are writing, that they blame the weight loss while you measured the first time when you were actually lighter. Ozempic does not enlarge your penis, but an erect penis may change size considerably depending on time of day, temperature, and factors other than sexual arousal. So it's probably just simply that," he explained. Other Ozempic Side Effects This is not the only side effect linked to the weight loss drug. Recently, some users reported "Ozempic teeth," characterised by various dental problems, including dry mouth, bad breath, gum disease, and tooth decay. According to reports, the drug's appetite-suppressing effect reduces food intake, which in turn decreases salivary gland stimulation. Reduced saliva flow increases the risk of cavities and gum issues. Additionally, some users experience nausea or vomiting, which can expose teeth to stomach acid, further eroding enamel. According to the New York Post, a doctor previously warned about "Ozempic mouth". The condition is marked by pronounced folds at the corners of the mouth, noticeable wrinkles on the lips, and sagging skin along the lip contours and chin area. Other complications include "Ozempic face" and "Ozempic butt". "Ozempic face" refers to the prematurely aged look some patients develop after shedding pounds at record speed. "Ozempic butt" on the other hand, refers to the saggy rear end some users are complaining about.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store